Proactive Investors - Run By Investors For Investors

AstraZeneca gets EU approval for Lynparza as ovarian cancer treatment

Pharma giant had been targeting annual peak sales of $2bn for the drug, of which $400mln was from ovarian cancer
ovarian cancer
In clinical trials, Lynparza demonstrated a 70% reduction in the risk of disease progression or death

AstraZeneca PLC’s (LON:AZN) Lynparza drug will be available in the European Union as a first-line maintenance treatment for women with advanced ovarian cancer.

The approval by the European Commission, the third indication for Lynparza in the EU, will make the drug available for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response following completion of first-line platinum-based chemotherapy.

READ: AstraZeneca reports positive results from trial of pancreatic cancer treatment

While 70% of women with ovarian cancer relapse within three years of initial chemo treatment, Lynparza, which is a result of a collaboration between AstraZeneca and MSD (Merck), has been proved to significantly increase progression-free survival. 

In the Phase III SOLO-1 trial testing Lynparza as maintenance monotherapy following chemotherapy, it demonstrated a 70% reduction in the risk of disease progression or death.

Following this new approval for Lynparza, the oncology collaboration with Merck dictates that AstraZeneca will receive $30mln as ongoing collaboration revenue, which the company anticipates will be booked during the second quarter of 2019.

Sales boost

Prior to its collaboration with Merck for Lynparza, AstraZeneca had been targeting annual peak sales of $2bn for the drug, of which $400mln was from ovarian cancer.

Broker Shore Capital noted that, to date, AstraZeneca has recognised circa $2.6bn from the Lynparza collaboration out of a total deal value of circa $8.5bn, of which $140mln relates to regulatory milestones.

"We also think that for FY2019F consensus is forecasting c$600m of Collaboration Revenue from the Merck collaboration, of which $100m is a final option payment (for combo trials between Merck’s Keytruda and Lynparza) and a further $500mln relating to regulatory and sales-milestones."

Astra shares were up 1% to 6,321.86p on Tuesday morning.

View full AZN profile View Profile

AstraZeneca Timeline

Related Articles

February 21 2019
Motif’s lead drug candidate is iclaprim, a next-generation antibiotic for which it was seeking US FDA approval for use in patients with acute bacterial skin and skin structure infections
April 05 2019
Chief executive Peter Butterfield said the company has started 2019 well-positioned for growth after a strong performance in 2018.
scientists in a lab
January 30 2019
The technology first drew the attention of ChemioCare CEO Pedro Lichtinger years ago while he oversaw Pfizer's global primary care business

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use